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ABSTRACT
A 40-year-old female patient with chronic persistent
cough was diagnosed with cough variant asthma
(CVA). To investigate the effect of suplatast tosilate
(suplatast, 300 mg/day, three times a day), cough
scores, medication scores, pulmonary function, cap-
saicin cough threshold, bronchial hyperresponsiveness
(BHR) to methacholine and eosinophilic cationic
protein (ECP) concentration in hypertonic saline-
induced sputum were evaluated before and after a
6-week treatment with suplatast. Treatment with
suplatast resulted in a marked decrease in persistent
cough and in the percentage of eosinophils and ECP
concentration in induced sputum. It also resulted in a
marked improvement in capsaicin cough threshold
and a slight improvement in BHR. These results
suggest that suplatast tosilate may be useful for treat-
ing patients with CVA.
Key words: asthma, capsaicin, cough threshold,
cough variant asthma, eosinophilic cationic protein,
suplatast, T helper 2 cell-derived cytokine inhibitor.
INTRODUCTION
Cough is one of the main symptoms of respiratory
disease. It has been reported that chronic persistent
cough is the only manifested clinical symptom in patients
with cough variant asthma (CVA).1,2 Episodic wheezing 
is one of the criteria of bronchial asthma, but there is 
no history of wheezing in CVA patients.1,2 Although the
precise mechanism responsible for the induction of
cough in CVA patients is not clear, bronchodilators, such
as b 2-adrenoreceptor agonist and theophylline, are
effective agents in relieving cough.3,4
Suplatast tosilate (suplatast) has been shown to inhibit
the production of Th2 cell-derived cytokines; interleukin
(IL)-4 and IL–5.5–7 Recently, suplatast has been reported
to be effective in mild asthma,8 but the effectiveness of
suplatast in the treatment of CVA has not been clearly
demonstrated.
In the present paper, we report on a case in which
suplatast improved persistent cough score and the cap-
saicin cough threshold and also induced a reduction in
the percentage of eosinophils and eosinophilic cationic
protein (ECP) concentration in hypertonic saline-induced
(induced) sputum, suggesting improvement in eosin-
ophilic inflammation.
CLINICAL SUMMARY
A 40-year-old female patient visited Akita University
Hospital on 12 May 1998, because of a dry cough that
had persisted for 6 months. Although she had been
treated with antibiotics and antitussive drugs by a general
physician since January 1998, her cough had not
improved. She had no history of asthma. Her cough
usually began at night and often disturbed her sleep. The
patient exhibited no wheezing, sputum, nasal discharge,
fever or other symptoms, including gastroesophageal
symptoms. The patient was 157 cm tall and weighed 
43 kg. Her blood pressure was 128/64 mmHg, with 
no difference between arms. Her pulse was regular 
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(96 b.p.m.). No heart murmur was heard and no rales
were heard over either lung field.
As shown in Table 1, the patient’s eosinophil differen-
tial was slightly elevated and her IgE level was within the
normal range. The radioallergosorbent test (RAST) scores
for house dust 1 (HD1), house dust mite (Der f), Japanese
cedar and dog skin were positive (2 + to 3 +; Table 1).
No abnormalities were detected by chest X-ray film or
electrocardiogram. Pulmonary function tests showed no
appreciable occlusion, with forced vital capacity (FVC) of
2.92 L, forced expiratory volume in 1 s (FEV1) of 2.43 L,
FEV1 as a percent of FVC (FEV1%) of 83.2% and peak
expiratory flow rate (PEF) of 4.43 L/sec (Table 2). There
were no significant changes in PEF values between the
morning and at night according to the asthma diary.
Bronchial response to inhaled methacholine (MCh)
was assessed with an Astograph (TCK-6100H; Chest,
Tokyo, Japan) for measurement of bronchial hyper-
responsiveness (BHR). This device uses the forced
oscillation method to measure respiratory resistance and
its reciprocal conductance during tidal breathing.9 Airway
sensitivity to MCh was expressed as the geometric mean
of the lowest concentration of MCh associated with the
start of a consistent decrease in conductance (Dmin, in
mg/mL (unit) of MCh inhalation). Airway reactivity to
MCh was expressed as the decrease rate of respiratory
conductance (SGrs, in L/s per cmH2O). Cough threshold
was evaluated using capsaicin. according to the method
of Midgren et al.10,11 Briefly, capsaicin (Sigma Chemical
Co., St Louis, MO, USA) was dissolved in ethanol and
diluted with 0.9% NaCl to 0.016, 0.08, 0.4, 2, 10, 50
and 250 m mol/L. Capsaicin was inhaled during tidal
breathing from a nebulizer (Nissho, Tokyo, Japan, out-
put 0.5 mL/min, mean mass diameter 5 m m). Concen-
trations of capsaicin were increased until the patient
coughed more than 5 times. The final concentration 
was taken as the cough threshold for capsaicin 
(Ccap: m mol/L).10
The patient evaluated her coughing four times a day,
every 6 h, and recorded the cough points in the diary. 
The evaluations were ‘quite often’ (21 times or more), 
4 points; ‘often’ (11–20 times), 3 points; ‘relatively
often’ (6–10 times), 2 points; ‘not often’ (5 times or
fewer), 1 point; and ‘none’, 0 points. The total cough
points in a day became the cough scores. Inhalation of
90 T SHIOYA ET AL.
Table 1 Laboratory findings on first visit
Hematology
ESR (mm/h) 11
RBC (/mm3) 412 · 104
Hb (g/dL) 13.7
WBC (/mm3) 7800
N 32%
Eos. 12%
Baso. 0%
Mono. 7%
Lymph. 49%
Plt (/mm3) 27.7 · 104
Biochemistry
TP (g/dL) 8.2
Alb. (g/dL) 4.7
GOT (U/L) 28
GPT (U/L) 28
LDH (U/L) 168
ALP (U/L) 62
T. Chol. (mg/dL) 161
BUN (mg/dL) 10
Cr (mg/dL) 0.7
Na (mEq/L) 140
K (mEq/L) 3.9
Cl (mEq/L) 101
Serology and immunology
CRP (mg/dL) 0.0
IgE (IU/mL) 172.1
RAST
HD1 3+
Der f 3+
Jpn. cedar 3+
Dog skin 2+
Sputum eos. 35%
ESR, erythrocyte sedimentation rate; RBC, red blood cells; Hb;
hemoglobin; WBC, white blood cells; N, neutrophils; Eos., eosinophils;
Baso., basophils; Mono., monocytes; Lymph., lymphocytes; Plt,
platelets; TP, total protein; Alb., albumin; GOT, glutamate oxaloac-
etate transaminase; GPT, glutamate pyruvate transaminase; LDH,
lactate dehydrogenase; ALP, alkaline phosphatase; T. Chol., total cho-
lesterol; BUN, blood urea nitrogen; Cr, creatinine; CRP, C-reactive
protein; RAST, radioallergosorbent test; HD, house dust.
Table 2 Time course in pulmonary function test
12 May 1998 28 July 1998
FVC (L) 2.92 3.07
FEV1 (L) 2.43 2.49
FEV1% 83.2 81.1
PEF (L/s) 4.43 4.67
Ccap (m mol/L) 2.0 50.0
Dmin (U) 3.8 6.2
SGrs (L/s per cmH2O) 0.08 0.07
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s;
FEV1%, FEV1 as a percentage of FVC (FEV1/FVC); PEF, peak expiratory
flow rate; Ccap, capsaicin cough threshold; Dmin, geometric mean of
the lowest concentration of methacholine associated with the start of a
consistent decrease in conductance (in mg/mL of inhalation); SGrs,
decreased rate of respiratory conductance.
the b 2 stimulant procaterol was also evaluated according 
to the standard set by the Japanese Society of Allergology,
by counting each inhalation as 0.5 points.12 Total inhal-
ation points in a day were evaluated as medication scores.
Astograph results showed a slight increase in BHR, with 
a Dmin of 3.8 units and SGrs of 0.08 L/s per cmH2O. In
contrast, the capsaicin cough threshold was markedly
increased, as indicated by a Ccap of 2.0 m mol/L.
Airway inflammation was determined by counting the
percentage of eosinophils and ECP cocentrations13 in
induced sputum. We used a radioimmunoassay14 with a
Pharmacia Kit (Pharmacia Co., Tokyo, Japan) to measure
the ECP concentration, which was elevated (4530 m g/L)
in induced sputum. The percentage of eosinophils in
induced sputum was 35%. We did not evaluate the
concentrations of IL-4 and IL-5 in the sputum.
The patient was treated with suplatast (300 mg/day
three times a day) beginning on 26 May, when testing
was completed. Her persistent cough improved clinically
beginning on treatment day 5. Treatment with suplatast
also resulted in significant improvement in the cough
scores, based on patient diary entries, and medication
scores, as determined by the frequency of b 2 stimulant
inhalation (Figs 1,2). Although there was no marked dif-
ference between the pulmonary function test results
before and after 6 weeks of treatment with suplatast,
Dmin improved slightly from 3.8 to 6.2 units and Ccap
improved markedly from 2.0 to 50.0 m mol/L (Table 2).
The IgE level was 168.2 IU/mL after the 6-week suplatast
treatment. No eosinophils were detected in induced
sputum after the 6-week treatment and the sputum 
ECP concentrations also fell markedly from 4530 to 
210 m g/L. The treatment with suplatast was continued
and the patient has been free from persistent cough.
DISCUSSION
Treatment with suplatast resulted in the reduction of persis-
tent cough, improvement in cough and medication scores,
slight improvement in BHR, and marked improvement 
in the capsaicin cough threshold in a patient with CVA.
Cough is one of the main symptoms of respiratory
disease. It is also not unusual for bronchial asthma
patients to experience coughing alone as their chief 
complaint. An extreme example of this is CVA, the patho-
physiology of which has been the focus of considerable
interest.1–4 Cough in CVA is elicited on the basis of the
cough receptor sensitivity and bronchoconstriction.15,16
Anatomic and physiologic research has shown that the
cough receptors that mark the starting point of the cough
reflex pathway comprise rapidly adapting stretch recep-
tors (RASR), located mainly in the central airways, and
bronchial or pulmonary c-fibers, found in the peripheral
airways.17 Substance P is regarded as one of the most
influential neurotransmitters in these receptors.18,19
Recently, suplatast has been shown to have immuno-
regulatory effects.5–7 Briefly, suplatast inhibits IgE pro-
duction and degranulation of basophils or mast cells
induced by IgE and suppresses production of IL-4 and 
IL-5 by T helper 2 (Th2) cells.5,6 Suplatast specifically
inhibits production of IgE antibodies, but not IgG and
IgM, in mice and also inhibits eosinophil infiltration in 
the same in vivo mouse model by suppressing Th2 cells.9
Treatment of patients with mild asthma has confirmed
that suplatast significantly reduces eosinophil infiltration
in the sputum and bronchial epithelium.8 Tsubura et al.
have reported moderate improvement in 52.9% of adult
bronchial asthma patients 5–6 weeks after treatment with
suplatast at a dose of 300 mg/day.20
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Fig. 1 Change in cough scores. Fig. 2 Change in medication scores.
Our patient was diagnosed with CVA because of the
absence of appreciable airway obstruction, although she
had slightly increased BHR and elevated eosinophil per-
centage and ECP concentration in induced sputum.
Treatment with suplatast, a Th2 cell-derived cytokine
inhibitor, markedly reduced the patient’s persistent cough
and also resulted in significant improvement in cough
and medication scores. The sputum eosinophil count
also fell significantly and there was a marked reduction 
in ECP concentration, suggesting an improvement in
eosinophilic inflammation. The Dmin, an objective indi-
cator of BHR, improved slightly from 3.8 units before
treatment to 6.2 units after treatment and Ccap, an
objective indicator of cough hypersensitivity, improved
significantly from 2.0 m mol/L to 50.0 m mol/L, suggesting
that suplatast may be useful for the treatment of cough 
in patients with CVA. Suplatast appeared to reduce
eosinophilic airway inflammation by suppressing the 
production of Th2 cell-derived inflammatory cytokines,
such as IL-4 and IL-5, as suggested by the marked reduc-
tion in sputum eosinophil count and ECP concentration
observed in our patient. However, inflammatory cytokines
such as IL-4 and IL-5 in the sputum need to be evaluated
to verify this hypothesis. In addition, suplatast produced
more a marked reduction of cough hypersensitivity than
BHR, suggesting that suplatast may have inhibited
eosinophilic inflammation of the cough RASR itself.
Further basic research is needed to explain the precise
mechanism by which suplatast inhibits cough in patients
with CVA. The usefulness and mechanism of action of
suplatast in relation to cough in CVA should be explored
in more detail by conducting a case-controlled study of
the drug in a large sample size at multiple institutions to
investigate cough hypersensitivity and BHR and further
evaluate sputum inflammatory cytokines.
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